Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.advisorKRAMER, Boris W.-
dc.contributor.authorDe Munter, Stephanie-
dc.description.abstractPerinatal hypoxic-ischemic encephalopathy (HIE) is a major cause of preterm brain injury. In the Western world, there has been a tremendous increase in preterm birth rates over the past 20 years and the incidence of perinatal HIE is estimated at two to six per 1000 live-born infants. Currently, few treatment options are available for preterms suffering from HIE. In this translational research project, we hypothesize that Mesenchymal Stem Cells (MSC) and Granulocyte-Colony Stimulating Factor (G-CSF) therapies can reduce hypoxic-ischemic related synapse loss, neurodegeneration, microglial proliferation and damage to pre-oligodendrocytes in a fetal sheep model, thereby limiting preterm HIE.-
dc.publishertUL Diepenbeek-
dc.titleCell therapy in neonatal hypoxic ischemic encephalopathy-
dc.typeTheses and Dissertations-
dc.description.notesmaster in de biomedische wetenschappen-klinische moleculaire wetenschappen-
local.type.specifiedMaster thesis-
item.fulltextWith Fulltext-
item.accessRightsOpen Access-
item.fullcitationDe Munter, Stephanie (2012) Cell therapy in neonatal hypoxic ischemic encephalopathy.-
Appears in Collections:Master theses
Files in This Item:
File Description SizeFormat 
08265992011249.pdf4.14 MBAdobe PDFView/Open
Show simple item record

Page view(s)

checked on Jun 24, 2022


checked on Jun 24, 2022

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.